Effects of TH-142177 on angiotensin II-induced proliferation, migration and intracellular signaling in vascular smooth muscle cells and on neointimal thickening after balloon injury

Nozawa, Yoshihisa; Matsuura, Naosuke; Miyake, Hidekazu; Yamada, Shizuo; Kimura, Ryohei

doi:10.1016/s0024-3205(99)00153-8

Cited by 28 publications

(25 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ARBs have beneficial effects in the treatment of heart failure, renal failure, and myocardial infarction. Studies of cultured VSMCs show that ARBs inhibit DNA synthesis, VSMC proliferation, and protein synthesis [13][14][15][16][17]. Moreover, olmesartan ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats [18].…”

Section: Introductionmentioning

confidence: 99%

Losartan Inhibits Vascular Smooth Muscle Cell Proliferation through Activation of AMP-Activated Protein Kinase

Kim

Choi

2010

Korean J Physiol Pharmacol

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Losartan Inhibits Vascular Smooth Muscle Cell Proliferation through Activation of AMP-Activated Protein Kinase

Kim

Choi

2010

Korean J Physiol Pharmacol

View full text Add to dashboard Cite

“…4 Moreover, Nozawa et al reported that ARBs blocked not only Ang II-induced neointimal DNA synthesis and cellular migration, but also neointimal thickening after balloon injury in rats. 53 Prasad et al found similar results in terms of improved endothelium-dependent relaxation in normotensive patients with atherosclerosis treated with ARBs. 54 Various HMG CoA reductase inhibitors (statins), have been shown to have a direct beneficial effect on endothelial function that is related, at least in part, to upregulation of the expression and activity of eNOS, independent of their cholesterol-lowering effect.…”

Section: The Clinical Role Of the No-ang Ii-o 2 -Axismentioning

confidence: 71%

Review: Interaction among angiotensin II, nitric oxide and oxidative stress

Zhou

Adam

Raij

2001

J Renin Angiotensin Aldosterone Syst

View full text Add to dashboard Cite

“…23 It has been reported that an ARB inhibits neointimal formation in the rat carotid injury model. 24 Patients receiving a low-dose oral administration of valsartan (80 mg/day), compared with placebo and ACE inhibitors in previous trials, showed a preventive effect on in-stent restenosis after BMS implantation. 25, 26 Conflicting results have been demonstrated with the use of other ARBs such as candesartan cilexetil 27 and losartan.…”

Section: Arb and In-stent Restenosismentioning

confidence: 94%

Beneficial Effects of Valsartan on Target Lesion Revascularization After Percutaneous Coronary Interventions With Bare-Metal Stents

Okada

Yamamoto

Okimoto

et al. 2011

Circ J

View full text Add to dashboard Cite

he growing use of coronary stents has improved the results of percutaneous coronary intervention (PCI) over the last decade. 1 However, in-stent restenosis continues to limit the long-term success of this procedure. 2 Drug-eluting stents (DES) coated with strong antiproliferative agents such as sirolimus or paclitaxel have dramatically reduced the need for repeat revascularization procedures due to reduction in restenosis rates after PCI. [3][4][5][6] Notwithstanding this tremendous progression in antirestenotic therapies, with the use of DES, target lesion revascularization (TLR) remains necessary in approximately 12% of patients at 2 years after PCI. 7 Moreover, there is increasing concern about the safety of DES, in light of reports that they are associated with a slightly increased rate of late stent thrombosis and possibly increased rates of myocardial infarction (MI) and death after PCI. 8 Although the efficacy of DES lies in reducing restenosis-related TLR, lesions at low risk of restenosis might still be considered suitable for bare-metal stents (BMS) in the contemporary DES era. 9 Previous studies have shown the benefits of angiotensin converting enzyme (ACE) inhibitors in patients with coronary artery disease. 10,11 In contrast, the effects of angiotensin II receptor blockers (ARBs) with coronary artery disease remain to be determined. While 2 open-label studies suggested beneficial effects of ARBs on neointimal proliferation at 6 months, 12,13 a smaller randomized open-label study did not show a reduction in neointimal proliferation for ARB-related patients after coronary stent implantation at 6 months. Background: Angiotensin II receptor blockers (ARB) have been shown to reduce cardiovascular events in patients at risk. The effect of valsartan on outcomes after percutaneous coronary interventions (PCI) with bare-metal stents (BMS) was investigated.

show abstract

Effects of TH-142177 on angiotensin II-induced proliferation, migration and intracellular signaling in vascular smooth muscle cells and on neointimal thickening after balloon injury

Cited by 28 publications

References 29 publications

Losartan Inhibits Vascular Smooth Muscle Cell Proliferation through Activation of AMP-Activated Protein Kinase

Losartan Inhibits Vascular Smooth Muscle Cell Proliferation through Activation of AMP-Activated Protein Kinase

Review: Interaction among angiotensin II, nitric oxide and oxidative stress

Beneficial Effects of Valsartan on Target Lesion Revascularization After Percutaneous Coronary Interventions With Bare-Metal Stents

Contact Info

Product

Resources

About